RhGUS: Phase III data

Top-line data from a double-blind, crossover, U.S. Phase III trial in 12 patients ages 5-35 with MPS VII showed that 4 mg/kg IV UX003 every other week for 24-48 weeks met the primary endpoint of reducing urinary GAG excretion after 24 weeks compared to

Read the full 444 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE